Brent Yoder
Family · Flomaton, ALNPI 1497831184
Payments from drug & device makers
Across 134 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$692
- Otsuka America Pharmaceutical, Inc.$273
- Novo Nordisk$140
- Bayer$137
- Paratek Pharmaceuticals, Inc.$95
- Shield Therapeutics Inc$78
- plus $796 from 18 others
What the payments were for
- Food & beverage$2,19699%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,211 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $44,783 |
| MounjaroTirzepatide | 41 | $44,259 |
| EliquisApixaban | 46 | $32,563 |
| LinzessLinaclotide | 30 | $28,318 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $18,980 |
| XareltoRivaroxaban | 20 | $16,469 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $10,192 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,004 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,269 |
| Pantoprazole Sodium | 259 | $3,021 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 149 | $2,713 |
| Novolog FlexpenInsulin Aspart | 13 | $2,356 |
| Omeprazole | 124 | $2,278 |
| Amlodipine Besylate | 260 | $1,793 |
| Rosuvastatin Calcium | 130 | $1,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $140 | $44,78345 claims |
| Lilly USA, LLCMounjaro | $78 | $44,25941 claims |
| PfizerEliquis | $73 | $32,56346 claims |
| AbbVieLinzess | $692 | $28,31830 claims |
| Johnson & JohnsonXarelto | $42 | $16,46920 claims |
| GSKBreo Ellipta | $26 | $4,26911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.
Other family in Flomaton
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.